{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:12:48Z","timestamp":1788369168783,"version":"build-2803163510"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003751","name":"Quebec Ministry of Health and Social Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020951","name":"Fonds de recherche du Qu\u00e9bec","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100020951","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Center","award":["CRC-2019-00055"],"award-info":[{"award-number":["CRC-2019-00055"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A 2-dose hepatitis B vaccination schedule is highly immunogenic in children aged \u22651 year, but data for infants are scarce. Our goal was to compare the immunogenicity of 2- and 3-dose hepatitis B vaccination schedules in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Children in the experimental group were recruited at 2 months of age and randomized to receive a homologous (Infanrix-hexa\/Infanrix-hexa) or heterologous (Infanrix-hexa\/Twinrix) 2-dose schedule at 2 and 12 months. Children in the control group were recruited at 18 months and had received a homologous 3-dose schedule (Infanrix-hexa\/Infanrix-hexa\/Infanrix-hexa) at 2, 4, and 18 months. All groups received a challenge dose (Twinrix) 3 years later.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One month after the primary series, seroprotection rates (anti-HBs \u226510 mIU\/mL) were high and similar among the 3 groups (heterologous 2-dose, 91.7%; homologous 2-dose, 90.9%; 3-dose, 94.2%). Geometric mean titers (GMTs) were lower in the 2-dose groups than in the 3-dose group. Post-challenge dose, the majority exhibited an anamnestic response, similar across all 3 groups (heterologous 2-dose, 97.2%; homologous 2-dose, 95.5%; 3-dose, 92.7%). GMTs were numerically higher in the heterologous 2-dose group (9380.5 mIU\/mL) than in the 3-dose group (6900.6 mIU\/mL) (P = .4). The proportion exhibiting local reactions was significantly lower after the heterologous 2-dose schedule than after the homologous 2-dose schedule.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The anamnestic response 3 years after 2-dose (2 and 12 months) and 3-dose (2, 4, and 18 months) hepatitis B vaccination schedules was similar. The heterologous 2-dose schedule was more immunogenic and less reactogenic than the homologous 2-dose schedule.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag122","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:41:40Z","timestamp":1771936900000},"page":"e243-e253","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity of Two Versus Three Doses of Hepatitis B Vaccine When Administered to Children Aged 2\u201318 Months: A Randomized Clinical Trial"],"prefix":"10.1093","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2086-0408","authenticated-orcid":false,"given":"Koffi Barnab\u00e9","family":"Kegbevi","sequence":"first","affiliation":[{"name":"D\u00e9partement de m\u00e9decine sociale et pr\u00e9ventive, Facult\u00e9 de m\u00e9decine, Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec ,","place":["Canada"]},{"name":"Axe maladies infectieuses et immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yossi","family":"Febriani","sequence":"additional","affiliation":[{"name":"Axe maladies infectieuses et immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4300-1658","authenticated-orcid":false,"given":"Chantal","family":"Sauvageau","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine sociale et pr\u00e9ventive, Facult\u00e9 de m\u00e9decine, Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec ,","place":["Canada"]},{"name":"Axe maladies infectieuses et immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec ,","place":["Canada"]},{"name":"Direction des risques biologiques, Institut national de sant\u00e9 publique du Qu\u00e9bec , Qu\u00e9bec, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4541-2567","authenticated-orcid":false,"given":"Marie-Michelle","family":"Ursu","sequence":"additional","affiliation":[{"name":"D\u00e9partement de microbiologie, infectiologie et immunologie, Facult\u00e9 de m\u00e9decine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, Qu\u00e9bec ,","place":["Canada"]},{"name":"Centre de recherche Azrieli du CHU Sainte-Justine Axe maladies infectieuses et soins aigus, , Montr\u00e9al, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1170-9475","authenticated-orcid":false,"given":"Caroline","family":"Quach","sequence":"additional","affiliation":[{"name":"D\u00e9partement de microbiologie, infectiologie et immunologie, Facult\u00e9 de m\u00e9decine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, Qu\u00e9bec ,","place":["Canada"]},{"name":"Centre de recherche Azrieli du CHU Sainte-Justine Axe maladies infectieuses et soins aigus, , Montr\u00e9al, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4028-8507","authenticated-orcid":false,"given":"Micha\u00ebl","family":"Desjardins","sequence":"additional","affiliation":[{"name":"D\u00e9partement de microbiologie, infectiologie et immunologie, Facult\u00e9 de m\u00e9decine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, Qu\u00e9bec ,","place":["Canada"]},{"name":"Centre de recherche du Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al Axe immunopathologie, , Montr\u00e9al, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bestman-Smith","sequence":"additional","affiliation":[{"name":"Axe maladies infectieuses et immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Gilca","sequence":"additional","affiliation":[{"name":"Direction des risques biologiques, Institut national de sant\u00e9 publique du Qu\u00e9bec , Qu\u00e9bec, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6042-3177","authenticated-orcid":false,"given":"Nicholas","family":"Brousseau","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine sociale et pr\u00e9ventive, Facult\u00e9 de m\u00e9decine, Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec ,","place":["Canada"]},{"name":"Axe maladies infectieuses et immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Qu\u00e9bec-Universit\u00e9 Laval , Qu\u00e9bec, Qu\u00e9bec ,","place":["Canada"]},{"name":"Direction des risques biologiques, Institut national de sant\u00e9 publique du Qu\u00e9bec , Qu\u00e9bec, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2026090212182401000_jiag122-B1","author":"World Health Organization"},{"key":"2026090212182401000_jiag122-B2","first-page":"369","article-title":"Vaccins anti-h\u00e9patite B: note de synth\u00e8se de l\u2019OMS\u2014juillet 2017","volume":"92","author":"Organisation mondiale de la sant\u00e9","year":"2017","journal-title":"Relev\u00e9 \u00e9pid\u00e9miologique hebdomadaire"},{"key":"2026090212182401000_jiag122-B3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/B978-0-323-79058-1.00027-X","volume-title":"Plotkin's vaccines (eighth edition) [internet]","author":"Ward","year":"2023"},{"key":"2026090212182401000_jiag122-B4","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/S0264-410X(02)00153-6","article-title":"Long term (24 months) follow-up of a hepatitis A and B vaccine, comparing a two and three dose schedule in adolescents aged 12\u201315 years","volume":"20","author":"Levie","year":"2002","journal-title":"Vaccine"},{"key":"2026090212182401000_jiag122-B5","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1016\/j.vaccine.2005.06.003","article-title":"Reactogenicity and immunogenicity profile of a two-dose combined hepatitis A and B vaccine in 1\u201311-year-old children","volume":"23","author":"Roberton","year":"2005","journal-title":"Vaccine"},{"key":"2026090212182401000_jiag122-B6","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1016\/j.vaccine.2006.12.021","article-title":"Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11\u201315 years: a randomised controlled trial","volume":"25","author":"Heron","year":"2007","journal-title":"Vaccine"},{"key":"2026090212182401000_jiag122-B7","author":"GlaxoSmithKline Inc"},{"key":"2026090212182401000_jiag122-B8","author":"GlaxoSmithKline Inc"},{"key":"2026090212182401000_jiag122-B9","author":"Dynavax Technologies Corporation"},{"key":"2026090212182401000_jiag122-B10","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(85)91726-X","article-title":"Hepatitis B immunisation with a reduced number of doses in newborn babies and children","volume":"1","author":"Piazza","year":"1985","journal-title":"Lancet"},{"key":"2026090212182401000_jiag122-B11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0923-2516(97)89893-7","article-title":"Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine","volume":"148","author":"Da Villa","year":"1997","journal-title":"Res Virol"},{"key":"2026090212182401000_jiag122-B12","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1016\/j.vaccine.2005.06.013","article-title":"Immunogenicity of a recombinant, yeast-derived, anti-hepatitis-B vaccine after alternative dosage and schedule vaccination in Pakistani children","volume":"23","author":"Akram","year":"2005","journal-title":"Vaccine"},{"key":"2026090212182401000_jiag122-B13","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0264-410X(99)00422-3","article-title":"Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8\u201310-year-old children","volume":"18","author":"Duval","year":"2000","journal-title":"Vaccine"},{"key":"2026090212182401000_jiag122-B14","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1016\/j.vaccine.2004.07.022","article-title":"Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8\u201310-year-old children","volume":"23","author":"Duval","year":"2005","journal-title":"Vaccine"},{"key":"2026090212182401000_jiag122-B15","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/INF.0b013e3181a3ad28","article-title":"Long-term immunogenicity of two pediatric doses of combined hepatitis a and b or monovalent hepatitis b vaccine in 8 to 10-year-old children and the effect of a challenge dose given seven years later","volume":"28","author":"Gilca","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"2026090212182401000_jiag122-B16","author":"Minist\u00e8re de la Sant\u00e9 et des Services sociaux"},{"key":"2026090212182401000_jiag122-B17","author":"Minist\u00e8re de la Sant\u00e9 et des Services sociaux"},{"key":"2026090212182401000_jiag122-B18","author":"Institut national de sant\u00e9 publique du Qu\u00e9bec"},{"key":"2026090212182401000_jiag122-B19","author":"Minist\u00e8re de la Sant\u00e9 et des Services sociaux"},{"key":"2026090212182401000_jiag122-B20","author":"Bio-Rad Laboratories"},{"key":"2026090212182401000_jiag122-B21","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.4161\/hv.29617","article-title":"Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9\u201310 year-old girls according to 0\u20136 month schedule","volume":"10","author":"Gilca","year":"2014","journal-title":"Hum Vaccin & Immunother"},{"key":"2026090212182401000_jiag122-B22","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1017\/ice.2015.147","article-title":"Short- and long-term effects of a challenge dose of hepatitis B vaccine in individuals with and without residual anti-HBs","volume":"36","author":"Gilca","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026090212182401000_jiag122-B23","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.vaccine.2011.12.106","article-title":"Persistence of long-term immunity to hepatitis B among adolescents immunized at birth","volume":"30","author":"Chaves","year":"2012","journal-title":"Vaccine"},{"key":"2026090212182401000_jiag122-B24","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.amepre.2020.03.009","article-title":"Immunogenicity of hepatitis B vaccine in preterm or low birth weight infants: a meta-analysis","volume":"59","author":"Fan","year":"2020","journal-title":"Am J Prev Med"},{"key":"2026090212182401000_jiag122-B25","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0140-6736(85)90704-4","article-title":"Two-dose hepatitis B immunisation regimen for infants","volume":"2","author":"Piazza","year":"1985","journal-title":"Lancet"},{"key":"2026090212182401000_jiag122-B26","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/JCM.02430-07","article-title":"Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen","volume":"46","author":"Huzly","year":"2008","journal-title":"J Clin Microbiol"},{"key":"2026090212182401000_jiag122-B27","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1586\/14760584.2016.1150182","article-title":"Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review","volume":"15","author":"Bakker","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"2026090212182401000_jiag122-B28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2893.1998.00101.x","article-title":"Production of antibody to hepatitis A virus and hepatitis B surface antigen measured after combined hepatitis A\/hepatitis B vaccination in 242 adult volunteers","volume":"5","author":"Reutter","year":"1998","journal-title":"J Viral Hepat"},{"key":"2026090212182401000_jiag122-B29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1086\/589722","article-title":"Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine","volume":"198","author":"Cardell","year":"2008","journal-title":"J Infect Dis"},{"key":"2026090212182401000_jiag122-B30","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1016\/j.vaccine.2008.08.054","article-title":"Improved cell mediated immune responses after successful re-vaccination of non-responders to the hepatitis B virus surface antigen (HBsAg) vaccine using the combined hepatitis A and B vaccine","volume":"26","author":"Nystr\u00f6m","year":"2008","journal-title":"Vaccine"},{"key":"2026090212182401000_jiag122-B31","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0264-410X(98)00421-6","article-title":"The first combined vaccine against hepatitis A and B: an overview","volume":"17","author":"Thoelen","year":"1999","journal-title":"Vaccine"},{"key":"2026090212182401000_jiag122-B32","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.2165\/00003495-200363230-00008","article-title":"Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability","volume":"63","author":"Murdoch","year":"2003","journal-title":"Drugs"},{"key":"2026090212182401000_jiag122-B33","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1586\/erv.09.32","article-title":"Review of 8 years of experience with infanrix hexa (DTPa\u2013HBV\u2013IPV\/hib hexavalent vaccine)","volume":"8","author":"Zepp","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"2026090212182401000_jiag122-B34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/21645515.2016.1225639","article-title":"Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV\/Hib in Indian infants","volume":"13","author":"Lalwani","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2026090212182401000_jiag122-B35","first-page":"E107","article-title":"Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts","volume":"59","author":"Orsi","year":"2018","journal-title":"J Prev Med Hyg"},{"key":"2026090212182401000_jiag122-B36","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.vaccine.2015.02.070","article-title":"Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad \u00ae) administered concomitantly with a booster dose of a hexavalent vaccine in 12\u201323-month-old infants","volume":"33","author":"Deichmann","year":"2015","journal-title":"Vaccine"},{"key":"2026090212182401000_jiag122-B37","doi-asserted-by":"crossref","first-page":"6688","DOI":"10.1016\/j.vaccine.2018.09.049","article-title":"Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa\u00ae) and MMRV (ProQuad\u00ae) at 18\u202fmonths of age","volume":"36","author":"Kiely","year":"2018","journal-title":"Vaccine"},{"key":"2026090212182401000_jiag122-B38","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.4161\/hv.34393","article-title":"The persistence of anti-HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy","volume":"10","author":"Bagheri-Jamebozorgi","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2026090212182401000_jiag122-B39","author":"National Advisory Committee on Immunization (NACI)"},{"key":"2026090212182401000_jiag122-B40","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0264-410X(96)00202-2","article-title":"Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders","volume":"15","author":"Goldwater","year":"1997","journal-title":"Vaccine"},{"key":"2026090212182401000_jiag122-B41","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.1016\/j.vaccine.2014.10.066","article-title":"Repeated vaccinations do not improve specific immune defenses against hepatitis B in non-responder health care workers","volume":"32","author":"Zaffina","year":"2014","journal-title":"Vaccine"},{"key":"2026090212182401000_jiag122-B42","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0264-410X(96)00205-8","article-title":"Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule\u2013results of a post-marketing surveillance","volume":"15","author":"Clemens","year":"1997","journal-title":"Vaccine"},{"key":"2026090212182401000_jiag122-B43","author":"GAVI, The Vaccine Alliance"},{"key":"2026090212182401000_jiag122-B44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/INF.0000000000000042","article-title":"Impact of the single-dose immunization strategy against hepatitis A in Argentina","volume":"33","author":"Vizzotti","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2026090212182401000_jiag122-B45","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3390\/vaccines8040780","article-title":"Universal single-dose vaccination against hepatitis A in children in a region of high endemicity","volume":"8","author":"Mikhailov","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"2026090212182401000_jiag122-B46","author":"Organisation mondiale de la Sant\u00e9"},{"key":"2026090212182401000_jiag122-B47","author":"Institut national de sant\u00e9 publique du Qu\u00e9bec"},{"key":"2026090212182401000_jiag122-B48","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00006454-199305000-00037","article-title":"Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies","volume":"12","author":"Greenberg","year":"1993","journal-title":"Pediatr Infect Dis J"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag122\/67112177\/jiag122.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/2\/e243\/67112177\/jiag122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/2\/e243\/67112177\/jiag122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:18:42Z","timestamp":1788365922000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/234\/2\/e243\/8497608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,25]]},"published-print":{"date-parts":[[2026,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag122","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,15]]},"published":{"date-parts":[[2026,2,25]]}}}